Comparative evaluation of fibric acid derivatives and HMG-CoA reductase inhibitors

This publication has 10 references indexed in Scilit:

• Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia
  The American Journal of Medicine, 1991
• National Cholesterol Education Program. Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction: executive summary. National Heart, Lung and Blood Institute, National Institutes of Health
  Archives of internal medicine (1960), 1991
• Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia
  Archives of internal medicine (1960), 1991
• Fenofibrate
  Drugs, 1990
• Effect of combined therapy with bezafibrate and cholestyramine on low-density lipoprotein metabolism in type IIa hypercholesterolemia
  Metabolism, 1989
• Apolipoprotein genetic variation and human disease
  Physiological Reviews, 1988
• Effects of fibrates on serum lipids and atherosclerosis
  Pharmacology & Therapeutics, 1988
• 3-Hydroxy-3-methylglutaryl--coenzyme A reductase inhibitors in the treatment of hypercholesterolemia
  Published by American Medical Association (AMA) ,1987
• Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects.
  Journal of Clinical Investigation, 1984
• Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects
  Atherosclerosis, 1982